CD38 is highly expressed by antibody-secreting cells (ASC) and depleting antibodies targeting CD38 have the potential to treat autoimmune diseases with ASC involvement. Here authors treat systemic lupus erythematosus patients with the ASC-depleting anti-CD38 monoclonal antibody daratumumab in addition to dexamethasone in the frame of a single arm, open-label phase 2 clinical trial to show marked improvements in their clinical and immunological status.
- Lennard Ostendorf
- Jan Zernicke
- Tobias Alexander